[Summary] Global integrated biopharmaceutical enterprise
2023 marks the 30th year since AstraZeneca entered China. Since 1993, AstraZeneca has adhered to its original aspiration of "patient-centricity," grounded in science, continuously expanding the frontiers of science, and driving innovative practices and sustainable development across drug R&D, production operations, and business models. Over the past three decades, AstraZeneca has remained committed to becoming a localized multinational pharmaceutical company that "brings in, takes root, and goes global." Leveraging its global advantageous resources and deep insights into the local Chinese pharmaceutical market, it continuously gathers global wisdom and strength while helping "Chinese innovation" reach the world, fulfilling the long-term commitment of "rooted in China, serving China, benefiting the globe."
AstraZeneca's China headquarters and the Global R&D China Center are located in Shanghai, with global production supply bases in Wuxi, Taizhou, and Qingdao, supplying high-quality medicines to approximately 70 global markets. To date, the company has cumulatively invested nearly USD 2 billion in China, and in recent years has established regional headquarters in Beijing, Guangzhou, Hangzhou, Chengdu, and Qingdao. Over the past 30 years, AstraZeneca has consistently focused on therapeutic areas of urgent need for Chinese patients, including oncology, cardiovascular, metabolic, renal, respiratory, digestive, rare diseases, vaccine antibodies, and autoimmune diseases, bringing nearly 40 innovative drugs to China.
After 30 years of deep cultivation in China, AstraZeneca continues to hold a positive outlook on China's R&D and innovation capabilities, increasing deployment and investment to elevate the speed and height of R&D innovation in China. In 2002, AstraZeneca pioneered global multicenter clinical trials in China; in 2007, it invested in establishing the China Innovation Center, focusing on unmet health needs of Chinese patients; in 2013, it established the China New Drug Development Department to support clinical development and launch of AstraZeneca's innovative drugs in China; in 2017, AstraZeneca partnered with SDIC Innovation to establish Dizal (Jiangsu) Pharmaceutical Co., Ltd., accelerating the pace of local new drug R&D; in 2019, it upgraded the New Drug Development Department to the Global R&D China Center, officially launched in Shanghai in 2021, deeply participating in global R&D and actively advancing global new drug development with strong Chinese R&D capabilities. Currently, there are over 180 projects in the China R&D pipeline, with a 100% synchronization rate for key projects with global R&D, and plans to introduce at least 15 new drugs (NMEs) in China within 5 years, with approximately 80 new drugs or new indications expected to be approved. It is also making forward-looking investments in disease areas where there remains substantial unmet medical need in China, collaborating to drive Chinese local innovation to the global stage and accelerate the delivery of high-quality innovative drugs to benefit more patients.
AstraZeneca thrives in symbiosis with the industry, joining forces with cross-sectoral entities including government, industry, academia, research, medical, and investment sectors. Guided by clear planning and innovation-driven development, it builds an international innovative health ecosystem through the "troika" of innovation: the China Centre for Innovative Healthcare (CCiC), the International Life Science Innovation Campus (iCampus), and the AstraZeneca CICC Medical Industry Fund. These efforts jointly promote regional economic and health industry long-term development. Currently, the diagnostic-treatment integrated innovative models supported by the CCiC have been implemented in thousands of hospitals nationwide, with some solutions also expanding abroad to more countries and regions. The iCampus integrates local industrial advantages to create a one-stop empowerment platform, forming a nationwide collaborative life science innovation ecosystem network, welcoming over 110 domestic and international enterprises. The AstraZeneca CICC Medical Industry Fund currently manages over RMB 3 billion in assets and has successfully invested in nearly 20 companies. In 2022, the fund initiated a new chapter of regional expansion, providing multidimensional empowerment for Chinese innovation across cycles and regions.
As a thirteen-time consecutive Outstanding Employer, cultivating local talent remains the cornerstone of AstraZeneca's long-term development in China. We actively develop domestic and international, cross-disciplinary talent development programs, uphold corporate values of "Science-led, Patient-first, Win with determination, Win with integrity, and Pioneer with courage," providing infinite possibilities for nurturing diverse local innovative talent with a global vision, pursuit of excellence, openness to collaboration, and fearlessness. Simultaneously, AstraZeneca in China highly fulfills its corporate social responsibility, actively engaging in diverse public welfare initiatives to jointly promote green and sustainable development for humanity, society, and the planet.
Standing at a new starting point of 30 years of establishment, AstraZeneca remains fully committed to forging ahead with determination, deepening investments in China, actively playing the role of an international bridge, advancing both "bringing in" and "going global" to benefit China and the world, joining forces to draw a blueprint for the health of all humanity.
What does AstraZeneca Investment (China) Co., Ltd. require? Who is AstraZeneca hiring? AstraZeneca recruitment: 医疗卫生/美容保健类占比最多占34.1%,其次是销售类占32.1%. What education can get in at AstraZeneca? 本科占比最多占65.8%,其次是大专占20.1%. High education required at AstraZeneca? 硕士占11.6%,博士占1.5%. Work experience required at AstraZeneca? 1-3年占比最多占32.8%,其次是不限占29.5%. Where are the job locations at AstraZeneca? 上海占比最多占22.3%,其次是无锡占6.9%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows